- Open Access
Human Immunodeficiency Virus type-1 reverse transcriptase exists as post-translationally modified forms in virions and cells
© Davis et al; licensee BioMed Central Ltd. 2008
Received: 01 August 2008
Accepted: 18 December 2008
Published: 18 December 2008
HIV-1 reverse transcriptase (RT) is a heterodimer composed of p66 and p51 subunits and is responsible for reverse transcription of the viral RNA genome into DNA. RT can be post-translationally modified in vitro which may be an important mechanism for regulating RT activity. Here we report detection of different p66 and p51 RT isoforms by 2D gel electrophoresis in virions and infected cells.
Major isoforms of the p66 and p51 RT subunits were observed, with pI's of 8.44 and 8.31 respectively (p668.44 and p518.31). The same major isoforms were present in virions, virus-infected cell lysates and intracellular reverse transcription complexes (RTCs), and their presence in RTCs suggested that these are likely to be the forms that function in reverse transcription. Several minor RT isoforms were also observed. The observed pIs of the RT isoforms differed from the pI of theoretical unmodified RT (p668.53 and p518.60), suggesting that most of the RT protein in virions and cells is post-translationally modified. The modifications of p668.44 and p518.31 differed from each other indicating selective modification of the different RT subunits. The susceptibility of RT isoforms to phosphatase treatment suggested that some of these modifications were due to phosphorylation. Dephosphorylation, however, had no effect on in vitro RT activity associated with virions, infected cells or RTCs suggesting that the phospho-isoforms do not make a major contribution to RT activity in an in vitro assay.
The same major isoform of p66 and p51 RT is found in virions, infected cells and RTC's and both of these subunits are post-translationally modified. This post-translational modification of RT may be important for the function of RT inside the cell.
The human immunodeficiency virus type 1 (HIV) reverse transcriptase (RT) enzyme catalyses reverse transcription of the viral RNA genome into double-stranded DNA in infected cells, a crucial early step in the virus life-cycle. RT is encoded by the Pol open reading frame, and is translated as a Gag-Pol protein precursor that is subsequently proteolysed by viral protease (PR) into 66 kDa (p66) and 51 kDa (p51) subunits with active RT formed as a heterodimer of p66 and p51 [1–3]. The p51 subunit shares the same N-terminal sequence but lacks the C-terminal 140 amino acids of p66. The subunits are functionally different: p66 possesses RNA-dependent and DNA-dependent DNA polymerase and RNase H activity, and p51 provides essential structural and conformational stability [4–7].
Reverse transcription of the viral RNA genome initially leads to synthesis of a 181 nt single-stranded, negative-sense DNA product called minus-strong stop DNA (-ssDNA) (reviewed in ). This first intermediate of reverse transcription is detected at low levels in a small proportion of intact virions [9–11] and although isolated intact HIV core structures can perform reverse transcription , following the entry of virions into cells, synthesis of -ssDNA and subsequent intermediate products of reverse transcription increases dramatically . The -ssDNA subsequently hybridises to the 3' terminus of the viral genome (first strand transfer) allowing negative strand DNA synthesis to continue . Plus strand DNA synthesis is initiated and following a second strand transfer, double-stranded viral DNA is completed. The kinetics of HIV reverse transcription during virus replication has been analysed in several studies [13–17], including a synchronous one-step cell-cell HIV infection model used in our laboratory which shows distinct time delays in the appearance of -ssDNA (1.5 hr post infection; pi), first strand transfer (2 hr pi) and second strand transfer DNA products (2.5 hr pi) . The presence of these time delays during reverse transcription has suggested that recruitment or modification of cellular and viral factors and/or conformational changes in RT may be required for specific steps of the reverse transcription process .
Protein phosphorylation is known to regulate the enzymatic activity of a number of proteins including polymerases. Phosphorylation of RNA polymerase II (RNAPII) is essential for transition from the initiation to elongation phase of transcription , while de-phosphorylation of RNAPII is required for re-forming a competent RNAPII initiation complex . Similarly, the HIV polymerase (or RT) may be regulated by phosphorylation. HIV RT can be phosphorylated in vitro by a number of kinases including auto-activated protein kinase (AK), myelin basic protein kinase (MBPK), cytosolic protamine kinase (CPK), casein kinase II (CKII) and protein kinase C (PKC) . Furthermore, CKII-mediated phosphorylation of RT stimulates polymerase and RNase H activity in vitro  and recombinant HIV RT can be phosphorylated in insect cells . Kinase-specific consensus sequences in HIV RT have also been found to be highly conserved within HIV subtypes [23, 24]. Together, these results suggest that the RT process is activated during early infection, that RT is a substrate for phosphorylation and that phosphorylation may affect RT activity. We therefore investigated whether HIV RT underwent post-translational modification, specifically phosphorylation, during the progression of a normal HIV infection.
We report that RT p66 and p51 exist in virions and during HIV infection of cells as a number of protein isoforms, some of which are phosphorylated. The majority of RT is post-translationally modified and the major RT isoforms are present in HIV RTCs, suggesting that these isoforms play a biological function in the reverse transcription process inside the cell.
Validation of pI measurements
Theoretical isoelectric point (pI)
No. of Phosphorylation groups
rRT LAI p66
rRT LAI p51
RT HXB2 p66
RT HXB2 p51
Observed pI of 6His-tagged recombinant RTLAI (rRT), and HIV-1 virion RTHXB2 p66 and p51 isoforms. Isoform in bold is the major isoform observed.
Observed isoelectric point (pI)
virion RT p66
virion RT p51
HIV RT exists as multiple isoforms
Summary of the routinely observed isoforms of RTHXB2.
phosphorylation + basic addition
aphosphorylation + basic addition or bdeamidation
a phosphorylation + basic addition
2 phosphates + basic addition
We next analysed RT present after HIV infected H3B cells were mixed with uninfected Hut-78 cells at 37°C to allow virus entry and replication. The same two major p668.44 and p518.31 isoforms were again observed (Figure 3B). However, the relative proportions of the major and minor isoforms differed, with the minor isoforms becoming more prominent and the major p668.44 and p518.31 isoforms representing only 64 ± 11 and 60 ± 9% of the p51 and p66 RT protein, respectively. Similar minor isoforms were present in these cells undergoing active reverse transcription compared with those detected in chronically infected virus producer H3B cells.
After viral entry some RT remains part of a nucleoprotein complex termed the reverse transcription complex (RTC) but the majority of virion associated RT dissociates from the RTC . We next assessed if specific isoforms of RT were associated with RTCs following HIV infection. Infections were initiated by cell-cell mixing as previously, and after 120 min, cell lysates were prepared and subjected to sucrose velocity gradient sedimentation. This sedimentation technique was chosen since we have previously observed that it yields good separation of free protein (fraction 1) and any remaining unactivated RT in pre-exisiting complexes from H3B cells (fraction 7) from RTCs (fraction 5) [2, 26], the latter which we can monitor by virtue of the presence of newly synthesised reverse transcription products. HIV reverse transcription products showed a peak in gradient fraction 5 (1.08 g/ml sucrose; Figure 3C) consistent with the previously characterised sedimentation rate of RTCs as defined by the presence of newly synthesised DNA, RT activity and HIV integrase protein . Sucrose gradient fractions were then subjected to 2D gel electrophoresis and western blot for RT, as above. Fraction 1 from the top of the gradient and containing free protein showed RT isoforms with migration characteristics consistent with p668.57, p668.44 and p518.41, p518.31, p518.15 and p517.91, with the major isoforms p668.44 and p518.31 (Figure 3D) as seen previously (Figure 2, 3A, 3B). However, in fraction 5 containing RTCs, only isoforms with migration characteristics consistent with p668.44 and p518.31 could be detected (Figure 3E). Although this does not exclude the presence of other less abundant RT isoforms in RTCs that were not detected due to the much lower levels of RT protein present, our results confirm that the major isoforms of p668.44 and p518.31 RT, seen in the virion and in infected cells, are associated with active RTCs and thus are the likely to be biologically relevant RT isoforms.
Newly HIV infected cells contain phosphorylated isoforms of RT
Removal of phosphate groups should increase protein pI if phosphorylation is present. Phosphatase treatment clearly altered the observed p66 and p51 isoforms (Figure 4B). The minor p66 isoforms, (p668.28 and p668.16) were greatly diminished or abolished by phosphatase treatment and this was reproducibly observed in replicate experiments, suggesting that these isoforms are phosphorylated. p668.16 differed by -0.37 pI units from the theoretical pI of unmodified p668.53, consistent with the -0.34 pI unit change associated with addition of a single phosphate group. This p668.16 phosphorylated isoform was not routinely detected in all experiments. p668.28 differed by -0.25 pI units from unmodified p66, suggesting that while p668.28 is phosphorylated it also possesses additional modifications which make it more basic. p517.91 was also consistently reduced by phosphatase treatment and differed by -0.69 pI units compared with unmodified p51, corresponding to a predicted addition of two phosphate groups and additional basic modification. Although most of p51 RT was relatively phosphatase resistant (Figure 4B) in one experiment phosphatase treatment reduced the levels of both p518.41 and p518.31 (data not shown). We have previously observed variation in de-phosphorylation and that total de-phosphorylation of ovalbumin is time-dependent; indicating slow removal of certain phosphate groups (CJ Bagley, unpublished results). Thus the variable susceptibly of some RT isoforms to de-phosphorylation may reflect reduced activity or restricted accessibility of the phosphatase enzyme to some phosphate groups present in the RT protein and thus we believe that p518.41 and p518.31 are most likely phosphorylated. Together the pI value and susceptibility to phosphatase treatment indicate that the RT isoforms p668.28, p668.16 and p517.91 and potentially p518.41 and p518.31 are phospho-RT isoforms.
Previous literature has suggested that RT may be subjected to post-translational modification, such as phosphorylation and it is well known that the process of reverse transcription is substantially activated upon cell infection. We thus hypothesised that this activation of RT may be related to its post-translational modification, particularly phosphorylation. In this study we have shown by 2D gel electrophoresis that modified RT forms are the major RT protein present in virions, newly infected cells and RTC's. The same predominant RT isoforms with pI's of p668.44 and p518.31 were seen in purified virions, intracellularly and associated with RTC's, and this suggests that these are the major biologically active RT form. The possibility that these represented an excess of inactive molecules present together with smaller levels of a modified active form, was considered unlikely since these forms predominated in semi-purified RTCs that are known to be supporting active reverse transcription. The major RT isoforms observed corresponded to an undefined post-translational modification for p668.44, and potentially phosphorylation plus an undefined basic modification for p518.31. The major p518.31 isoform had lower pI than the major p668.44 isoform, contrary to that seen for recombinant RT (p668.13 and p518.33) and the theoretical pI of the unmodified p518.60 or p668.53. Additionally, susceptibility of p518.31 to phosphatase treatment in one experiment suggested that p518.31 may be phosphorylated, while p668.44 was phosphatase resistant in all instances. Thus the major p518.31 isoform contains modifications that are different from those in the major p668.44 isoform. This observed differential modification of p51 compared to p66 may be the result of (i) modification of a single p66 molecule of the RT homodimer that is then selectively targeted for cleavage giving rise to p51 and a mature RT heterodimer or (ii) selective modification of the p51 in the heterodimer post p66 cleavage. This differential modification of p51 and p66 may be important for selective regulation of RT enzymatic functions via p66 post-translational modifications or alterations to RT structure/conformation via post-translational modifications of p51. The identification of these RT isoforms is novel. Previous studies have identified at least two isoforms of MA and CA [28–30] in HIV virions by 2D gel electrophoresis analysis followed by silver stain or western blot, but these studies have not identified isoforms of RT, possibly due to lower levels of RT or the use of isoelectric focussing strips of insufficient resolving power for the pI range of RT [30, 31]. The RT isoforms we observed changed little between virus producer cells, virions and newly infected cells, although the minor RT isoforms became more abundant following infection.
Some of the RT isoforms detected were phosphorylated, as suggested by their pI value and their susceptibility to dephosphorylation. Phosphorylation is known to modulate the activity of many proteins that interact with nucleic acids, including HIV proteins Tat, and Rev [32, 33] and RNAPII [19, 34]. Indeed phosphorylation of HIV RT in vitro led to increased polymerase and RNase H activities [21, 22, 35]. Similarly the phosphorylated forms of RT that we have identified may lead to p66/p51 heterodimers with different physical characteristics, activities or functionality and hence may play an important role in regulating reverse transcription in newly infected cells. Our results, however, show that dephosphorylation of RT from virions, cells lysates or RTCs had no effect on in vitro RT activity. This is not surprising given our results showing that the major isoforms that would be present in samples from virions, infected cells and RTCs are p668.44 and p518.31 that are not phosphorylated, and were phosphatase resistant in 2/3 experiments, respectively. Thus, naturally occurring phospho-RT isoforms are not a major contributor to RT activity, as measured in vitro, but could still be important for RT activity in the complex milieu of the infected cell, or may play a role in important structural interactions required for stability, movement and activity of the RTC intracellularly. Conclusive analysis of the roles of phosphorylation at specific sites in the RT enzyme remain to be determined by mutagenesis of potential RT phosphorylation sites and analysis of subsequent 2D gel electrophoresis profiles. However, at present this kind of analysis is hampered by the reduced sensitivity for detection of RT following infection with cell-free virus and 2D gel analysis, as would be necessitated in these experiments.
In conclusion, we describe for the first time the presence of modified p66 and p51 RT isoforms and report that the same major p518.31 and p668.44 isoforms are present in HIV virions, newly infected cells and active RTCs and thus are likely to be the forms playing a significant role in the reverse transcription process. The major p518.31 and p668.44 isoforms are modified differently, demonstrating selective modification of the RT subunits and although some RT isoforms are phosphorylated, phospho-isoforms of RT are not a major contributor to the inherent activity of RT, as measured in an in vitro activity assay. A better understanding of the post-translational modifications, the cellular enzymes involved and how these specifically influence RT activity inside the cell will be essential in elucidating the mechanisms for control of reverse transcription in newly infected cells.
Cells, virus and recombinant RT
H3B cells are a laboratory clone of H9 cells persistently infected with the HTLV-IIIB (HXB2) strain of HIV-1 . Virus particles were isolated from clarified H3B cell culture medium by filtration (Sartorius, 0.22 μm filter), concentration (100,000 MwCO centrifugal filter, Millipore) and pelleting through 25% (w/v) sucrose at 86,500 g, 4°C for 1.5 hr (Beckman Optima™ TLX Ultracentrifuge). Recombinant RT (p6HRT; hexahistidine-tagged p66/p51 heterodimer, Dr. Nicolas Sluis-Cremer, University of Pittsburgh and derived from p6HRT-PROT ) was from the LAI sequence of HIV-1  and produced by expression in M15 Escherichia coli and purified as described previously . Purified recombinant RT was generously provided by Dr. Gilda Tachedjian, Burnet Institute, Melbourne, Australia.
Cell-to-cell infection and lysis
H3B cells were mixed with Hut-78 cells at a ratio of 1:4 and incubated for 3 hr at 23°C to produce a temperature-arrested stage of infection . Cells were then shifted to 37°C to allow infection to proceed. To extract protein, 1 × 108 cells were washed twice in ice-cold PBS and lysed by rotating at 4°C for 1 hr in 1 ml lysis buffer (5 mM Tris-HCl pH 7.4, 50 mM KCl, 0.05 mM spermine, 0.125 mM spermidine, 2 mM DTT, protease inhibitors [20 μg/ml aprotonin, complete mini protease inhibitor tablet (Roche), 2 mM PMSF), phosphatase inhibitors (2 mM NaF, 10 mM sodium pyrophosphate, 2 mM sodium orthovanadate], and 0.2% (v/v) Triton X-100). The cell lysate was clarified twice by centrifugation at 17,000 g/4°C for 30 min before immunoprecipitation.
Immunoprecipitation of viral protein from infected cell lysate
Sera from four HIV-1 positive patients were pooled and heat-inactivated (AIDS patient sera (APS)) and incubated with protein A sepharose CL-4B beads (Pharmacia) at 4°C, rotating for 16 hr. Antibody was cross-linked to protein A using 5 mg/ml dimethyl pimelimidate (DMP) (Pierce) as described previously . To immunoprecipitate viral proteins, cell lysates were incubated with APS-protein A sepharose CL-4B for 16 hr rotating at 4°C. The beads were then pelleted by low-speed centrifugation and washed in ice-cold water three times then proteins eluted directly into 2D gel electrophoresis buffer (see below).
Fractionation of HIV reverse transcription complexes
HIV RTCs were fractionated on sucrose gradients as described previously [26, 41]. Briefly, infections were initiated by mixing of H3B and Hut-78 cells, as described above. At 120 min post mixing cells were harvested, washed, lysed in buffer containing 0.1% (v/v) Triton X-100 and subjected to 15–30% sucrose velocity gradient sedimentation or 0–60% sucrose equilibrium density gradient sedimentation. 1 ml fractions were collected from the top of the gradient and 1/10th of each fraction was analysed for HIV reverse transcription products by real time PCR. The remainder of the velocity gradient fractions were TCA precipitated and 85 μg of the total protein from each fraction was subjected to 2D gel electrophoresis, as below.
2D gel electrophoresis and Western blot analysis of protein
Samples were solubilised directly in 2D buffer (7 M urea, 2 M thiourea, 2% (w/v) CHAPS, and 0.5% pH 7–11 NL carrier ampholytes) and spiked with 3 μg glyceraldehyde-3-phosphate dehydrogenase (GAPDH, from rabbit muscle, Sigma) and 65 mM DTT. Samples (100 μl) were loaded, by anodic cup loading, onto a pH 7–11 non-linear, 11 cm Immobiline DryStrip (GE Healthcare) gel which had been hydrated in 2D sample buffer containing 1.2% (v/v) 2-hydroxethyldisulfide. Gels were run in a step-wise voltage gradient: 0–300 V/2 hr; 300–500 V/2 hr; 500–1000 V/2 hr; 1000–4000 V/5 hr followed by 4000 V/3 hr and then maintained at 500 V. Total volt hours (V/hr) ranged between 25–30,000 V/h. Focused proteins from individual gel strips were then separated by SDS-PAGE, using a 10% or 12% gel with a 29:1 acrylamide:bis-acrylamide ratio, alongside BenchMark™ prestained protein markers (Invitrogen), before transferring to PVDF transfer membrane (Hybond™-P; GE Healthcare). Membranes were blocked for 1 hr in TBST (50 mM Tris pH 7.4, 135 mM NaCl, 0.1% (v/v) Tween-20) containing 5% (w/v) skim-milk powder before incubating with rabbit anti-RT antibody (1:5000 dilution), (NIH AIDS Research and Reference Reagent Program, Dr. Stuart Le Grice, Division of AIDS, NIAID, NIH). Bound antibody was detected using horseradish-peroxidase-conjugated goat anti-rabbit IgG secondary antibody, and visualised using Super Signal West Dura Extended Duration Substrate (Pierce) and Kodak BioMax film (Integrated Sciences). To determine the relative proportion of p66 and p51 isoforms, protein spots in were quantitated by volume integration (Imagequant v3.3, Molecular Dynamics) and expressed as a percent of the total intensity of signal for RT p66 or p51.
Phosphatase treatment of viral proteins
Viral proteins were immunoprecipitated from infected cell lysates with APS conjugated protein A sepharose CL-4B beads as described above, virions were prepared by PEG precipitation of high titre virus supernatant, and RTCs were prepared by equilibrium gradient sedimentation, as above. One half of each sample was treated with 40 units of calf intestinal alkaline phosphatase (CIAP; Promega) in CIAP buffer; (50 mM Tris, pH 9.3, 1 mM MgCl2 0.1 mM ZnCl2 and 1 mM spermidine and protease inhibitors (20 ug/ml aprotonin, complete mini protease inhibitor tablet [Roche], 2 mM PMSF). The other half was resuspended in CIAP buffer, protease and phosphatase inhibitors (2 mM PMSF, 2 mM NaF, 10 mM sodium pyrophosphate, 2 mM sodium orthovanadate). Reactions were incubated 37°C for 1.5 hr. For subsequent 2D gel analysis, bead bound samples from cell lysates were pelleted, washed in ice-cold water three times and the bound virus protein was eluted in 2D gel electrophoresis sample buffer. For subsequent RT activity assay, reactions were used directly, without further processing.
RT activity assay
RT activity was quantitated in vitro using an exogenous activity assay. Briefly, microtitre plates (Covalink, Nunc) were coated with poly-A (Roche) then incubated with RT mix containing the test sample with 4.2 μM Digoxigenin (DIG)-UTP (Roche Diagnostics) and 2.5 μg/ml Oligo dT12–18 (GE Healthcare) in 8.4 μM dTTP, 25 mM KCl, 6.25 mM MgCl2, 62.5 mM Tris, pH 7.8, 1.25 mM DTT, 0.1% (v/v) Triton X-100, overnight at 37°C. Polymerised DIG-UTP was detected with anti-DIG-HRP conjugate (Roche Diagnostics, at 1/2500 dilution), reacted with 3,3',5,5'-tetramethylbenzidine (TMB substrate, Sigma) and quantitated by measurement of OD at 490 nm. Recombinant Moloney Murine leukemia virus (M-MuLV, New England Biolabs) was used as a comparative standard.
Estimation of protein isoelectric point
The distance migrated along the IEF strip from the loading point (anodic, pH 7 end) was measured as a percentage of the total gel-strip length (11 cm) and the pI calculated from an idealised pH 7–11 non-linear migration reference graph (GE Healthcare). For internal calibration, GAPDH was spiked into individual viral protein samples before focusing and small puncture holes made in the PVDF membrane were used to align the Coomassie-stained and the Western blot images. Theoretical pI values for unmodified HIVHXB2 p66 and p51 (Swiss-Prot: P04585), recombinant hexahistidine-tagged p66 and p51 proteins, and GAPDH , with one or more phosphate or deamidation modifications, in 8 M urea, were calculated using pKa values as used by the ExPASy Compute pI/Mw tool http://au.expasy.org/tools/pi_tool.html with the assumption that the pKa values of the protein's phosphate groups were 2.1 and 7.2.
We would like to thank Adrian Purins for maintenance of cell culture stocks, Megan Retallick for 2D gel electrophoresis, John Karlis and Carl Coolen for technical assistance. We also acknowledge Dr. Gilda Tachedjian for generously providing the purified recombinant RT protein. This work and AJD was supported by an Australian NHMRC project grant. JMC was supported by the Australian Centre for HIV and Hepatitis Research.
- Chattopadhyay D, Evans DB, Deibel MR, Vosters AF, Eckenrode FM, Einspahr HM, Hui JO, Tomasselli AG, Zurcher-Neely HA, Heinrikson RL, et al: Purification and characterization of heterodimeric human immunodeficiency virus type 1 (HIV-1) reverse transcriptase produced by in vitro processing of p66 with recombinant HIV-1 protease. J Biol Chem. 1992, 267: 14227-14232.PubMedGoogle Scholar
- Li P, Stephenson AJ, Brennan PA, Karageorgos L, Kok T, Kuiper LJ, Swift J, Burrell CJ: Initiation of reverse transcription during cell-to-cell transmission of human immunodeficiency virus infection uses pre-existing reverse transcriptase. J Gen Virol. 1994, 75 (Pt 8): 1917-1926. 10.1099/0022-1317-75-8-1917.View ArticlePubMedGoogle Scholar
- di Marzo Veronese F, Copeland TD, DeVico AL, Rahman R, Oroszlan S, Gallo RC, Sarngadharan MG: Characterization of highly immunogenic p66/p51 as the reverse transcriptase of HTLV-III/LAV. Science. 1986, 231: 1289-1291. 10.1126/science.2418504.View ArticlePubMedGoogle Scholar
- Tachedjian G, Aronson HE, de los Santos M, Seehra J, McCoy JM, Goff SP: Role of residues in the tryptophan repeat motif for HIV-1 reverse transcriptase dimerization. J Mol Biol. 2003, 326: 381-396. 10.1016/S0022-2836(02)01433-X.View ArticlePubMedGoogle Scholar
- Hostomsky Z, Hostomska Z, Fu TB, Taylor J: Reverse transcriptase of human immunodeficiency virus type 1: functionality of subunits of the heterodimer in DNA synthesis. J Virol. 1992, 66: 3179-3182.PubMed CentralPubMedGoogle Scholar
- Hizi A, McGill C, Hughes SH: Expression of soluble, enzymatically active, human immunodeficiency virus reverse transcriptase in Escherichia coli and analysis of mutants. Proc Natl Acad Sci USA. 1988, 85: 1218-1222. 10.1073/pnas.85.4.1218.PubMed CentralView ArticlePubMedGoogle Scholar
- Mulky A, Sarafianos SG, Arnold E, Wu X, Kappes JC: Subunit-specific analysis of the human immunodeficiency virus type 1 reverse transcriptase in vivo. J Virol. 2004, 78: 7089-7096. 10.1128/JVI.78.13.7089-7096.2004.PubMed CentralView ArticlePubMedGoogle Scholar
- Harrich D, Hooker B: Mechanistic aspects of HIV-1 reverse transcription initiation. Rev Med Virol. 2002, 12: 31-45. 10.1002/rmv.339.View ArticlePubMedGoogle Scholar
- Zhang H, Pomerantz RJ, Dornadula G, Sun Y: Human immunodeficiency virus type 1 Vif protein is an integral component of an mRNP complex of viral RNA and could be involved in the viral RNA folding and packaging process. J Virol. 2000, 74: 8252-8261. 10.1128/JVI.74.18.8252-8261.2000.PubMed CentralView ArticlePubMedGoogle Scholar
- Huang M, Martin MA: Incorporation of Pr160(gag-pol) into virus particles requires the presence of both the major homology region and adjacent C-terminal capsid sequences within the Gag-Pol polyprotein. J Virol. 1997, 71: 4472-4478.PubMed CentralPubMedGoogle Scholar
- Arts EJ, Mak J, Kleiman L, Wainberg MA: Mature reverse transcriptase (p66/p51) is responsible for low levels of viral DNA found in human immunodeficiency virus type 1 (HIV-1). Leukemia. 1994, 8 (Suppl 1): S175-178.PubMedGoogle Scholar
- Warrilow D, Stenzel D, Harrich D: Isolated HIV-1 core is active for reverse transcription. Retrovirology. 2007, 4: 77-10.1186/1742-4690-4-77.PubMed CentralView ArticlePubMedGoogle Scholar
- Li P, Burrell CJ: Synthesis of human immunodeficiency virus DNA in a cell-to-cell transmission model. AIDS Res Hum Retroviruses. 1992, 8: 253-259.View ArticlePubMedGoogle Scholar
- Li P, Stephenson AJ, Kuiper LJ, Burrell CJ: Double-stranded strong-stop DNA and the second template switch in human immunodeficiency virus (HIV) DNA synthesis. Virology. 1993, 194: 82-88. 10.1006/viro.1993.1237.View ArticlePubMedGoogle Scholar
- Kim SY, Byrn R, Groopman J, Baltimore D: Temporal aspects of DNA and RNA synthesis during human immunodeficiency virus infection: evidence for differential gene expression. J Virol. 1989, 63: 3708-3713.PubMed CentralPubMedGoogle Scholar
- Barbosa P, Charneau P, Dumey N, Clavel F: Kinetic analysis of HIV-1 early replicative steps in a coculture system. AIDS Res Hum Retroviruses. 1994, 10: 53-59.View ArticlePubMedGoogle Scholar
- Vandegraaff N, Kumar R, Burrell CJ, Li P: Kinetics of human immunodeficiency virus type 1 (HIV) DNA integration in acutely infected cells as determined using a novel assay for detection of integrated HIV DNA. J Virol. 2001, 75: 11253-11260. 10.1128/JVI.75.22.11253-11260.2001.PubMed CentralView ArticlePubMedGoogle Scholar
- Karageorgos L, Li P, Burrell CJ: Stepwise analysis of reverse transcription in a cell-to-cell human immunodeficiency virus infection model: kinetics and implications. J Gen Virol. 1995, 76 (Pt 7): 1675-1686. 10.1099/0022-1317-76-7-1675.View ArticlePubMedGoogle Scholar
- Payne JM, Laybourn PJ, Dahmus ME: The transition of RNA polymerase II from initiation to elongation is associated with phosphorylation of the carboxyl-terminal domain of subunit IIa. J Biol Chem. 1989, 264: 19621-19629.PubMedGoogle Scholar
- Archambault J, Chambers RS, Kobor MS, Ho Y, Cartier M, Bolotin D, Andrews B, Kane CM, Greenblatt J: An essential component of a C-terminal domain phosphatase that interacts with transcription factor IIF in Saccharomyces cerevisiae. Proc Natl Acad Sci USA. 1997, 94: 14300-14305. 10.1073/pnas.94.26.14300.PubMed CentralView ArticlePubMedGoogle Scholar
- Idriss H, Kawa S, Damuni Z, Thompson EB, Wilson SH: HIV-1 reverse transcriptase is phosphorylated in vitro and in a cellular system. Int J Biochem Cell Biol. 1999, 31: 1443-1452. 10.1016/S1357-2725(99)00097-7.View ArticlePubMedGoogle Scholar
- Harada S, Haneda E, Maekawa T, Morikawa Y, Funayama S, Nagata N, Ohtsuki K: Casein kinase II (CK-II)-mediated stimulation of HIV-1 reverse transcriptase activity and characterization of selective inhibitors in vitro. Biol Pharm Bull. 1999, 22: 1122-1126.View ArticlePubMedGoogle Scholar
- Gordon M, De Oliveira T, Bishop K, Coovadia HM, Madurai L, Engelbrecht S, Janse van Rensburg E, Mosam A, Smith A, Cassol S: Molecular characteristics of human immunodeficiency virus type 1 subtype C viruses from KwaZulu-Natal, South Africa: implications for vaccine and antiretroviral control strategies. J Virol. 2003, 77: 2587-2599. 10.1128/JVI.77.4.2587-2599.2003.PubMed CentralView ArticlePubMedGoogle Scholar
- Ojesina AI, Sankale JL, Odaibo G, Langevin S, Meloni ST, Sarr AD, Olaleye D, Kanki PJ: Subtype-specific patterns in HIV Type 1 reverse transcriptase and protease in Oyo State, Nigeria: implications for drug resistance and host response. AIDS Res Hum Retroviruses. 2006, 22: 770-779. 10.1089/aid.2006.22.770.View ArticlePubMedGoogle Scholar
- Fassati A, Goff SP: Characterization of intracellular reverse transcription complexes of human immunodeficiency virus type 1. J Virol. 2001, 75: 3626-3635. 10.1128/JVI.75.8.3626-3635.2001.PubMed CentralView ArticlePubMedGoogle Scholar
- Carr JM, Davis AJ, Coolen C, Cheney K, Burrell CJ, Li P: Vif-deficient HIV reverse transcription complexes (RTCs) are subject to structural changes and mutation of RTC-associated reverse transcription products. Virology. 2006, 351: 80-91. 10.1016/j.virol.2006.03.027.View ArticlePubMedGoogle Scholar
- Guthridge MA, Stomski FC, Barry EF, Winnall W, Woodcock JM, McClure BJ, Dottore M, Berndt MC, Lopez AF: Site-specific serine phosphorylation of the IL-3 receptor is required for hemopoietic cell survival. Mol Cell. 2000, 6: 99-108. 10.1016/S1097-2765(00)00011-3.View ArticlePubMedGoogle Scholar
- Fouchier RA, Simon JH, Jaffe AB, Malim MH: Human immunodeficiency virus type 1 Vif does not influence expression or virion incorporation of gag-, pol-, and env-encoded proteins. J Virol. 1996, 70: 8263-8269.PubMed CentralPubMedGoogle Scholar
- Fuchigami T, Misumi S, Takamune N, Takahashi I, Takama M, Shoji S: Acid-labile formylation of amino terminal proline of human immunodeficiency virus type 1 p24(gag) was found by proteomics using two-dimensional gel electrophoresis and matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry. Biochem Biophys Res Commun. 2002, 293: 1107-1113. 10.1016/S0006-291X(02)00329-7.View ArticlePubMedGoogle Scholar
- Misumi S, Fuchigami T, Takamune N, Takahashi I, Takama M, Shoji S: Three isoforms of cyclophilin A associated with human immunodeficiency virus type 1 were found by proteomics by using two-dimensional gel electrophoresis and matrix-assisted laser desorption ionization-time of flight mass spectrometry. J Virol. 2002, 76: 10000-10008. 10.1128/JVI.76.19.10000-10008.2002.PubMed CentralView ArticlePubMedGoogle Scholar
- Gaddis NC, Chertova E, Sheehy AM, Henderson LE, Malim MH: Comprehensive investigation of the molecular defect in vif-deficient human immunodeficiency virus type 1 virions. J Virol. 2003, 77: 5810-5820. 10.1128/JVI.77.10.5810-5820.2003.PubMed CentralView ArticlePubMedGoogle Scholar
- Holmes AM: In vitro phosphorylation of human immunodeficiency virus type 1 Tat protein by protein kinase C: evidence for the phosphorylation of amino acid residue serine-46. Arch Biochem Biophys. 1996, 335: 8-12. 10.1006/abbi.1996.0476.View ArticlePubMedGoogle Scholar
- Fouts DE, True HL, Cengel KA, Celander DW: Site-specific phosphorylation of the human immunodeficiency virus type-1 Rev protein accelerates formation of an efficient RNA-binding conformation. Biochemistry. 1997, 36: 13256-13262. 10.1021/bi971551d.View ArticlePubMedGoogle Scholar
- Parada CA, Roeder RG: Enhanced processivity of RNA polymerase II triggered by Tat-induced phosphorylation of its carboxy-terminal domain. Nature. 1996, 384: 375-378. 10.1038/384375a0.View ArticlePubMedGoogle Scholar
- Lazaro JB, Boretto J, Selmi B, Capony JP, Canard B: Phosphorylation of AZT-resistant human immunodeficiency virus type 1 reverse transcriptase by casein kinase II in vitro: effects on inhibitor sensitivity. Biochem Biophys Res Commun. 2000, 275: 26-32. 10.1006/bbrc.2000.3251.View ArticlePubMedGoogle Scholar
- Le Grice SF, Gruninger-Leitch F: Rapid purification of homodimer and heterodimer HIV-1 reverse transcriptase by metal chelate affinity chromatography. Eur J Biochem. 1990, 187: 307-314. 10.1111/j.1432-1033.1990.tb15306.x.View ArticlePubMedGoogle Scholar
- Shi C, Mellors JW: A recombinant retroviral system for rapid in vivo analysis of human immunodeficiency virus type 1 susceptibility to reverse transcriptase inhibitors. Antimicrob Agents Chemother. 1997, 41: 2781-2785.PubMed CentralPubMedGoogle Scholar
- Tachedjian G, Moore KL, Goff SP, Sluis-Cremer N: Efavirenz enhances the proteolytic processing of an HIV-1 pol polyprotein precursor and reverse transcriptase homodimer formation. FEBS Lett. 2005, 579: 379-384. 10.1016/j.febslet.2004.11.099.View ArticlePubMedGoogle Scholar
- Mkrtchyan SR, Markosyan RM, Eadon MT, Moore JP, Melikyan GB, Cohen FS: Ternary complex formation of human immunodeficiency virus type 1 Env, CD4, and chemokine receptor captured as an intermediate of membrane fusion. J Virol. 2005, 79: 11161-11169. 10.1128/JVI.79.17.11161-11169.2005.PubMed CentralView ArticlePubMedGoogle Scholar
- Schneider C, Newman RA, Sutherland DR, Asser U, Greaves MF: A one-step purification of membrane proteins using a high efficiency immunomatrix. J Biol Chem. 1982, 257: 10766-10769.PubMedGoogle Scholar
- Karageorgos L, Li P, Burrell C: Characterization of HIV replication complexes early after cell-to-cell infection. AIDS Res Hum Retroviruses. 1993, 9: 817-823.View ArticlePubMedGoogle Scholar
- Cowan-Jacob SW, Kaufmann M, Anselmo AN, Stark W, Grutter MG: Structure of rabbit-muscle glyceraldehyde-3-phosphate dehydrogenase. Acta Crystallogr D Biol Crystallogr. 2003, 59: 2218-2227. 10.1107/S0907444903020493.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.